The drug Trodelvy (drug name sacituzumab govitecan-hziy) is showing promise for first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors (treatments that ...

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in metastatic ...

Dr Heather McArthur describes how ASCO 2025 showcased new standards of care in triple-negative and HER2-positive settings.

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression free ...

Interim results reveal promising efficacy and safety of sacituzumab govitecan and pembrolizumab for muscle-invasive bladder ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- Treatment with single-agent sacituzumab govitecan (Trodelvy) offered no survival advantage over docetaxel in ...

Sacituzumab govitecan-hziy significantly improved progression free survival over standard chemotherapy in untreated mTNBC patients ineligible for immunotherapy. Topline data were announced from a ...

Treatment with pembrolizumab and the antibody-drug conjugate (ADC) sacituzumab govitecan improved progression-free survival (PFS) in patients with PD-L1-positive locally advanced or metastatic ...

Sacituzumab govitecan targets Trop-2 and delivers potent chemo directly to TNBC cells. PARP inhibitors are effective in TNBC patients with BRCA mutations. Immune checkpoint inhibitors benefit ...

Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor conjugate. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...